GlassScriptPhysician profile
Judith Goldberg
NPI 1912986571
$5,110.00
in general payments reported to CMS, 2019-2025
30 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,689 · 2020: $517 · 2021: $62.46 · 2022: $583 · 2023: $581 · 2024: $478 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214 · Education: $45.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.52 |
| Education | $45.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,242.19 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $520.69 | 2019-2025 | Mounjaro, Zepbound |
| Radius Health, INC. | $329.19 | 2019-2022 | |
| Abbott Laboratories | $327.62 | 2019-2024 | Freestyle Libre 3 |
| Mannkind Corporation | $310.65 | 2019-2023 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $309.28 | 2019-2023 | Farxiga |
| Abbvie INC. | $258.36 | 2019-2025 | |
| Novo Nordisk INC | $243.80 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $199.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $192.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.21 | 2019-2020 | |
| Ibsa Pharma INC. | $155.45 | 2019-2024 | Tirosint, Licart, Licart |
| Merck Sharp & Dohme LLC | $144.63 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $139.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $91.89 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $85.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.98 | 2019-2020 | |
| Esperion Therapeutics, INC. | $39.12 | 2024-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.06 | 2019 | |
| Exact Sciences Corporation | $34.20 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $34.03 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $33.16 | 2019 | |
| Mission Pharmacal Company | $26.07 | 2019 | |
| Corcept Therapeutics | $23.29 | 2024 | Korlym |
| Madrigal Pharmaceuticals | $22.15 | 2025 | Rezdiffra |
| Insulet Corporation | $20.12 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.20 | 2023 | |
| Acella Pharmaceuticals, LLC | $17.66 | 2025 | NP Thyroid 60 |
| Currax Pharmaceuticals LLC | $16.37 | 2025 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $15.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.